Extrawell Pharmaceutical Holdings Limited reported to the Hong Kong Stock Exchange that there were no changes to its share capital structure for the month ended 31 March 2026.

Authorised and Issued Capital • Authorised share capital remained at 20.00 billion ordinary shares with a par value of HKD 0.01, equivalent to HKD 200.00 million. • Issued share count was unchanged at 2.55 billion ordinary shares. The company held no treasury shares.

Public Float • Extrawell confirmed full compliance with the Main Board’s minimum 25% public-float requirement as of 31 March 2026.

Equity Incentives • The 2022 Share Option Scheme shows 76.50 million options outstanding, representing the same level as the prior month. No options were exercised or cancelled, and no new options were granted. The scheme still allows up to 162.50 million shares to be issued upon future exercises.

Convertible Instruments • The company has HKD 577.17 million zero-coupon convertible bonds due 2033 outstanding. The bonds are convertible at HKD 0.6413 per share, carrying a potential dilution of up to 900.00 million new shares if fully converted. No conversions occurred during March.

Liquidity and Treasury Activity • There were no share repurchases, redemptions, treasury-share movements, warrant exercises, or other equity-linked issuances during the reporting period.

Conclusion Extrawell Pharmaceutical’s March 2026 return indicates a steady capital structure, with 2.55 billion shares in issue, no treasury stock, and ample authorised headroom for future corporate actions via its option scheme and outstanding convertible bonds.